Paul Grayson

Mr. Paul A. Grayson is a Chairman at Skye Bioscience, Inc., a President, Chief Executive Officer & Director at Radionetics Oncology, Inc., a Member at Aurora Biosciences Corp.
and a President & Chief Executive Officer at RuiYi, Inc. (China).
He is on the Board of Directors at Radionetics Oncology, Inc. Mr. Grayson was previously employed as a President & Chief Executive Officer by Tentarix Biotherapeutics LP, a President, Chief Executive Officer & Director by Tentarix Biotherapeutics, Inc., a Venture Partner by Versant Venture Management LLC, a President, Chief Executive Officer & Director by Bird Rock Bio Sub, Inc., a President & Chief Executive Officer by Fate Therapeutics, Inc., a Managing Director by Sanderling Management CO LLC, a President & Chief Executive Officer by Senomyx, Inc., a Chairman by CalciMedica Subsidiary, Inc., and a Chairman by Naviscan, Inc. He also served on the board at Progenitor Labs Ltd., Apoptos, Inc., Chimerix, Inc., Pipeline Therapeutics, Inc., Receptos LLC, Ren Pharmaceuticals, Inc. and TempestTx, Inc. He received his undergraduate degree from the University of California, Los Angeles and an MBA from the University of California, Irvine.